{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T23:55:23Z","timestamp":1793058923443,"version":"4.5.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2023,10,2]],"date-time":"2023-10-02T00:00:00Z","timestamp":1696204800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,10,2]],"date-time":"2023-10-02T00:00:00Z","timestamp":1696204800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100010571","name":"Bundesministerium f\u00fcr Bildung, Wissenschaft, Forschung und Technologie","doi-asserted-by":"publisher","award":["01ZX1506"],"award-info":[{"award-number":["01ZX1506"]}],"id":[{"id":"10.13039\/501100010571","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["SFB873"],"award-info":[{"award-number":["SFB873"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Hairy Cell Leukemia Foundation, Else Kr\u00f6ner Fresenius Foundation, Heidelberg Research Center for Molecular Medicine"},{"name":"Heidelberg School of Oncology (HSO2) fellowship from the National Center for Tumor Diseases (NCT) Heidelberg"},{"name":"Franziska-Kolb Foundation"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Ex vivo drug response profiling is a powerful tool to study genotype\u2013drug response associations and is being explored as a tool set for precision medicine in cancer. Here we conducted a prospective non-interventional trial to investigate feasibility of ex vivo drug response profiling for treatment guidance in hematologic malignancies (SMARTrial,\n                    <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03488641\">NCT03488641<\/jats:ext-link>\n                    ). The primary endpoint to provide drug response profiling reports within 7\u2009d was met in 91% of all study participants (\n                    <jats:italic>N<\/jats:italic>\n                    \u2009=\u200980). Secondary endpoint analysis revealed that ex vivo resistance to chemotherapeutic drugs predicted chemotherapy treatment failure in vivo. We confirmed the predictive value of ex vivo response to chemotherapy in a validation cohort of 95 individuals with acute myeloid leukemia treated with daunorubicin and cytarabine. Ex vivo drug response profiles improved ELN-22 risk stratification in individuals with adverse risk. We conclude that ex vivo drug response profiling is clinically feasible and has the potential to predict chemotherapy response in individuals with hematologic malignancies beyond clinically established genetic markers.\n                  <\/jats:p>","DOI":"10.1038\/s43018-023-00645-5","type":"journal-article","created":{"date-parts":[[2023,10,2]],"date-time":"2023-10-02T12:02:13Z","timestamp":1696248133000},"page":"1648-1659","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":50,"title":["Ex vivo drug response profiling for response and outcome prediction in hematologic malignancies: the prospective non-interventional SMARTrial"],"prefix":"10.1038","volume":"4","author":[{"given":"Nora","family":"Liebers","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9992-3109","authenticated-orcid":false,"given":"Peter-Martin","family":"Bruch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Terzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"Hernandez-Hernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nagarajan","family":"Paramasivam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donnacha","family":"Fitzgerald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heidi","family":"Altmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6973-3531","authenticated-orcid":false,"given":"Tobias","family":"Roider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolin","family":"Kolb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mareike","family":"Knoll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Lenze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uwe","family":"Platzbecker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"R\u00f6llig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0748-834X","authenticated-orcid":false,"given":"Claudia","family":"Baldus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8472-5516","authenticated-orcid":false,"given":"Hubert","family":"Serve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Bornh\u00e4user","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6041-7049","authenticated-orcid":false,"given":"Daniel","family":"H\u00fcbschmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7166-5232","authenticated-orcid":false,"given":"Carsten","family":"M\u00fcller-Tidow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0653-5332","authenticated-orcid":false,"given":"Friedrich","family":"St\u00f6lzel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0474-2218","authenticated-orcid":false,"given":"Wolfgang","family":"Huber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel","family":"Benner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7890-9845","authenticated-orcid":false,"given":"Thorsten","family":"Zenz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junyan","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0648-1832","authenticated-orcid":false,"given":"Sascha","family":"Dietrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,10,2]]},"reference":[{"key":"645_CR1","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/j.mayocp.2013.01.019","volume":"88","author":"JR Mikhael","year":"2013","unstructured":"Mikhael, J. R. et al. Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013. Mayo Clin. Proc. 88, 360\u2013376 (2013).","journal-title":"Mayo Clin. Proc."},{"key":"645_CR2","doi-asserted-by":"publisher","first-page":"v69","DOI":"10.1093\/annonc\/mdw025","volume":"27","author":"D Hoelzer","year":"2016","unstructured":"Hoelzer, D. et al. Acute lymphoblastic leukaemia in adult patients: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 27, v69\u2013v82 (2016).","journal-title":"Ann. Oncol."},{"key":"645_CR3","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","volume":"36","author":"R Alaggio","year":"2022","unstructured":"Alaggio, R. et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: lymphoid neoplasms. Leukemia 36, 1720\u20131748 (2022).","journal-title":"Leukemia"},{"key":"645_CR4","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1182\/blood.2022016867","volume":"140","author":"H Dohner","year":"2022","unstructured":"Dohner, H. et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood 140, 1345\u20131377 (2022).","journal-title":"Blood"},{"key":"645_CR5","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","volume":"36","author":"JD Khoury","year":"2022","unstructured":"Khoury, J. D. et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: myeloid and histiocytic\/dendritic neoplasms. Leukemia 36, 1703\u20131719 (2022).","journal-title":"Leukemia"},{"key":"645_CR6","doi-asserted-by":"publisher","first-page":"1852","DOI":"10.1038\/s41591-020-1089-8","volume":"26","author":"A Burd","year":"2020","unstructured":"Burd, A. et al. Precision medicine treatment in acute myeloid leukemia using prospective genomic profiling: feasibility and preliminary efficacy of the Beat AML Master Trial. Nat. Med. 26, 1852\u20131858 (2020).","journal-title":"Nat. Med."},{"key":"645_CR7","doi-asserted-by":"publisher","first-page":"2780","DOI":"10.1158\/2159-8290.CD-21-0126","volume":"11","author":"P Horak","year":"2021","unstructured":"Horak, P. et al. Comprehensive genomic and transcriptomic analysis for guiding therapeutic decisions in patients with rare cancers. Cancer Discov. 11, 2780\u20132795 (2021).","journal-title":"Cancer Discov."},{"key":"645_CR8","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1038\/nm.4389","volume":"23","author":"A Letai","year":"2017","unstructured":"Letai, A. Functional precision cancer medicine\u2014moving beyond pure genomics. Nat. Med. 23, 1028\u20131035 (2017).","journal-title":"Nat. Med."},{"key":"645_CR9","doi-asserted-by":"publisher","first-page":"S63","DOI":"10.1038\/537S63a","volume":"537","author":"V Prasad","year":"2016","unstructured":"Prasad, V. The precision-oncology illusion. Nature 537, S63 (2016).","journal-title":"Nature"},{"key":"645_CR10","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1172\/JCI93801","volume":"128","author":"S Dietrich","year":"2018","unstructured":"Dietrich, S. et al. Drug-perturbation-based stratification of blood cancer. J. Clin. Invest. 128, 427\u2013445 (2018).","journal-title":"J. Clin. Invest."},{"key":"645_CR11","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1158\/2159-8290.CD-21-0538","volume":"12","author":"C Kornauth","year":"2022","unstructured":"Kornauth, C. et al. Functional precision medicine provides clinical benefit in advanced aggressive hematologic cancers and identifies exceptional responders. Cancer Discov. 12, 372\u2013387 (2022).","journal-title":"Cancer Discov."},{"key":"645_CR12","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1158\/2159-8290.CD-21-0410","volume":"12","author":"D Malani","year":"2022","unstructured":"Malani, D. et al. Implementing a functional precision medicine tumor board for acute myeloid leukemia. Cancer Discov. 12, 388\u2013401 (2022).","journal-title":"Cancer Discov."},{"key":"645_CR13","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1038\/s41375-018-0357-9","volume":"33","author":"N Daver","year":"2019","unstructured":"Daver, N., Schlenk, R. F., Russell, N. H. & Levis, M. J. Targeting FLT3 mutations in AML: review of current knowledge and evidence. Leukemia 33, 299\u2013312 (2019).","journal-title":"Leukemia"},{"key":"645_CR14","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1038\/nm.3788","volume":"21","author":"SM Chan","year":"2015","unstructured":"Chan, S. M. et al. Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia. Nat. Med. 21, 178\u2013184 (2015).","journal-title":"Nat. Med."},{"key":"645_CR15","doi-asserted-by":"publisher","first-page":"3148","DOI":"10.1182\/blood.V84.9.3148.3148","volume":"84","author":"E Wattel","year":"1994","unstructured":"Wattel, E. et al. p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies. Blood 84, 3148\u20133157 (1994).","journal-title":"Blood"},{"key":"645_CR16","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1182\/blood.V89.2.601","volume":"89","author":"WH Wilson","year":"1997","unstructured":"Wilson, W. H. et al. Relationship of p53, BCL-2, and tumor proliferation to clinical drug resistance in non-Hodgkin\u2019s lymphomas. Blood 89, 601\u2013609 (1997).","journal-title":"Blood"},{"key":"645_CR17","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","volume":"57","author":"Y Benjamini","year":"1995","unstructured":"Benjamini, Y. & Hochberg, Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J. R. Stat. Soc. B Methodol. 57, 289\u2013300 (1995).","journal-title":"J. R. Stat. Soc. B Methodol."},{"key":"645_CR18","doi-asserted-by":"crossref","unstructured":"Popova, A. A. et al. Miniaturized drug sensitivity and resistance test on patient-derived cells using droplet-microarray. SLAS Technol. 26, 274\u2013286 (2020).","DOI":"10.1177\/2472630320934432"},{"key":"645_CR19","doi-asserted-by":"publisher","first-page":"1900100","DOI":"10.1002\/adtp.201900100","volume":"3","author":"AA Popova","year":"2020","unstructured":"Popova, A. A. & Levkin, P. A. Precision medicine in oncology: in vitro drug sensitivity and resistance test (DSRT) for selection of personalized anticancer therapy. Adv. Ther. 3, 1900100 (2020).","journal-title":"Adv. Ther."},{"key":"645_CR20","doi-asserted-by":"publisher","first-page":"100914","DOI":"10.1016\/j.xpro.2021.100914","volume":"2","author":"T Roider","year":"2021","unstructured":"Roider, T., Brinkmann, B. J. & Dietrich, S. Processing human lymph node samples for single-cell assays. STAR Protoc. 2, 100914 (2021).","journal-title":"STAR Protoc."},{"key":"645_CR21","doi-asserted-by":"publisher","first-page":"e10855","DOI":"10.15252\/msb.202110855","volume":"18","author":"PM Bruch","year":"2022","unstructured":"Bruch, P. M. et al. Drug\u2013microenvironment perturbations reveal resistance mechanisms and prognostic subgroups in CLL. Mol. Syst. Biol. 18, e10855 (2022).","journal-title":"Mol. Syst. Biol."},{"key":"645_CR22","unstructured":"Kensche, P. R., Heinold, M. & Lammers, F. Alignment and quality control plugin for Roddy. GitHub https:\/\/github.com\/DKFZ-ODCF\/AlignmentAndQCWorkflows (2022)."},{"key":"645_CR23","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.jbiotec.2017.08.006","volume":"261","author":"E Reisinger","year":"2017","unstructured":"Reisinger, E. et al. OTP: an automatized system for managing and processing NGS data. J. Biotechnol. 261, 53\u201362 (2017).","journal-title":"J. Biotechnol."},{"key":"645_CR24","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1038\/ng.2682","volume":"45","author":"D Jones","year":"2013","unstructured":"Jones, D. et al. Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma. Nat. Genet. 45, 927\u2013932 (2013).","journal-title":"Nat. Genet."},{"key":"645_CR25","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1038\/s41586-020-1969-6","volume":"578","author":"The ICGC\/TCGA Pan-Cancer Analysis of Whole Genomes Consortium.","year":"2020","unstructured":"The ICGC\/TCGA Pan-Cancer Analysis of Whole Genomes Consortium. Pan-cancer analysis of whole genomes. Nature 578, 82\u201393 (2020).","journal-title":"Nature"},{"key":"645_CR26","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1186\/s12859-022-04983-6","volume":"23","author":"A Boudry","year":"2022","unstructured":"Boudry, A. et al. Frugal alignment-free identification of FLT3-internal tandem duplications with FiLT3r. BMC Bioinformatics 23, 448 (2022).","journal-title":"BMC Bioinformatics"},{"key":"645_CR27","doi-asserted-by":"publisher","first-page":"e0146021","DOI":"10.1371\/journal.pone.0146021","volume":"10","author":"C Ritz","year":"2015","unstructured":"Ritz, C., Baty, F., Streibig, J. C. & Gerhard, D. Dose\u2013response analysis using R. PLoS ONE 10, e0146021 (2015).","journal-title":"PLoS ONE"},{"key":"645_CR28","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1002\/sim.1836","volume":"23","author":"J Li","year":"2004","unstructured":"Li, J. & Fine, J. On sample size for sensitivity and specificity in prospective diagnostic accuracy studies. Stat. Med. 23, 2537\u20132550 (2004).","journal-title":"Stat. Med."}],"container-title":["Nature Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s43018-023-00645-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43018-023-00645-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43018-023-00645-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,29]],"date-time":"2024-10-29T17:30:55Z","timestamp":1730223055000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s43018-023-00645-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,2]]},"references-count":28,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["645"],"URL":"https:\/\/doi.org\/10.1038\/s43018-023-00645-5","relation":{},"ISSN":["2662-1347"],"issn-type":[{"value":"2662-1347","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,2]]},"assertion":[{"value":"13 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 August 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 October 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}